In order to further verify whether the CK regulation of the HIF-1α ubiquitination degradation-mediated glycolysis pathway in hypoxic hepatocellular carcinoma involved Bclaf1, we used CRISPR/Cas9 technology to knock out Bclaf1 expression (Figure 5A), and then evaluated the expression of HIF-1α and its ubiquitination-related proteins after CK treatment. The gene discussed is BCLAF1; the disease is hepatocellular carcinoma.